Skip to search formSkip to main contentSkip to account menu

ANG4043

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Immunoconjugates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Using ANG4043, a brain-penetrant anti-HER2 mab, to increase survival in a murine intracranial breast tumor model.
e13013 Background: Treatments for metastatic brain tumors originating from HER2-positive breast disease are limited due to the… 
2015
2015
Abstract 2465: Targeting HER2-positive brain metastases by incorporating the brain-penetrant Angiopep-2 peptide to an anti-HER2 antibody and anti-HER2 antibody drug conjugate
Monoclonal antibodies directed against receptor tyrosine kinases such as HER2 have been demonstrated to reduce tumor size and… 
2014
2014
Abstract 2657: Utilization of the Angiopep platform to enable brain penetration of therapeutic mAbs or Antibody-Drug Conjugates for treatment of brain tumors
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Monoclonal antibodies directed against receptor tyrosine… 
2013
2013
Abstract P6-11-05: ANG4043, a brain-penetrant anti-HER2 mAb increases survival in mice bearing intracranial BT-474 breast tumor cells
Background: Treatment options for metastatic brain tumors originating from HER2-positive breast disease are limited due to the… 
2013
2013
Abstract 864: ANG4043: A new brain-penetrant peptide-antibody conjugate that reduces tumor growth in a HER2-positive orthotopic tumor model.
While monoclonal antibodies to receptor tyrosine kinases such as HER2 have been demonstrated to reduce tumor size and increase… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)